Maravai LifeSciences Holdings (FRA:MAR) ROE % Adjusted to Book Value : -14.03% (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Maravai LifeSciences Holdings ROE % Adjusted to Book Value?

Maravai LifeSciences Holdings's ROE % for the quarter that ended in Dec. 2024 was -32.13%. Maravai LifeSciences Holdings's PB Ratio for the quarter that ended in Dec. 2024 was 2.29. Maravai LifeSciences Holdings's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 was -14.03%.

Maravai LifeSciences Holdings ROE % Adjusted to Book Value Historical Data

The historical data trend for Maravai LifeSciences Holdings's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Maravai LifeSciences Holdings ROE % Adjusted to Book Value Chart

Maravai LifeSciences Holdings Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

5.44

15.73

-11.70

-17.44

Maravai LifeSciences Holdings Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															-43.02	-4.22	-3.13	-29.73	-14.03

Competitive Comparison of Maravai LifeSciences Holdings's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Maravai LifeSciences Holdings's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Maravai LifeSciences Holdings's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Maravai LifeSciences Holdings's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Maravai LifeSciences Holdings's ROE % Adjusted to Book Value falls into.

Save Embed

;

Save Embed

;

Maravai LifeSciences Holdings ROE % Adjusted to Book Value Calculation

Maravai LifeSciences Holdings's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-39.93%	/	2.29
	=	-17.44%

Maravai LifeSciences Holdings's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-32.13%	/	2.29
	=	-14.03%

Maravai LifeSciences Holdings ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Maravai LifeSciences Holdings's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Maravai LifeSciences Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Maravai LifeSciences Holdings Inc (FRA:MAR) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

MRVI:USA MAR:Germany

Address

10770 Wateridge Circle, Suite 200, San Diego, CA, USA, 92121

Website

https://www.maravai.com

Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.